Compare DexCom, Inc. (DXCM) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Natera Inc. Common Stock — how do they compare? DexCom, Inc. trades at $86 (market cap $31.51B), while Natera Inc. Common Stock trades at $392.78 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and DexCom, Inc. is more actively traded (3,480,291 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Natera Inc. Common Stock for 0 Days on average.
| DXCM | NTRA | |
|---|---|---|
Market Cap | $31.51B | $57.03B |
Volume | 3,480,291 | 1,131,157 |
Sector | Health | Health |
52-Week High | $92.34 | $425.64 |
52-Week Low | $54.84 | $179.42 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $30.96B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $85.06, down 1.0% on the day, with a bullish technical signal and strong fundamental momentum. The stock is supported by consistent earnings beats, robust revenue growth from $4.0B in 2024 to $4.7B in 2025, and expanding net profit margins to 17.93%. Recent news highlights growth opportunities in Type 2 diabetes care and leadership appointments, reinforcing positive sentiment. Key resistance sits at $87, with immediate support at $85.
The outlook remains favorable given analyst consensus of a $96.14 price target and 80.77% buy ratings, though risks include competitive pressures and reimbursement challenges. Upside is driven by CGM adoption growth, while execution on guidance and market expansion are critical for sustained performance.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
